Mastering oligonucleotide formulations: a computational chemistry approach
Using multiscale computational chemistry simulations to reduce experimental tests and speed time-to-market
Oligonucleotide therapeutics represent one of the most promising frontiers in modern medicine. As demand for precision formulation grows, so does the need for faster, smarter development strategies. This white paper explores how multiscale computational chemistry simulations, integrated with Digital Twin technology, can model, predict and optimize oligonucleotide formulations from early-stage design through manufacturing.
The formulation challenge: complexity at scale
Oligonucleotide therapeutics represent one of the most promising frontiers in modern medicine, yet traditional formulation development relies on time-consuming empirical testing that cannot keep pace with industry demands. This white paper demonstrates how multiscale computational chemistry simulations, integrated with Digital Twin technology, enable pharmaceutical R&D teams to model, predict and optimize oligonucleotide formulations from early-stage design through manufacturing while reducing experimental burden and accelerating time-to-market.
The solution: computational intelligence meets pharmaceutical science
Siemens Simcenter™ Culgi™ software, part of the Siemens Xcelerator platform, provides a structured computational workflow that transforms oligonucleotide formulation development. By leveraging multiscale simulations and coarse-grained molecular modeling, R&D teams can virtually investigate molecular interactions, predict viscosity profiles and optimize buffer conditions before conducting physical experiments.
Why this matters now
The pharmaceutical industry faces significant pressure to accelerate R&D while maintaining the highest quality and regulatory standards. Digital formulation development using predictive Digital Twins enables organizations to make data-driven decisions, reduce development cycles and bridge the gap between theoretical design and practical manufacturing. This approach is particularly valuable in preclinical studies where the initial set of drug candidates is too large to synthesize through traditional methods.
Download the white paper today.